Clinical trials: Androgenic Alopecia
Androgenetic Alopecia, Hair Loss
Treatment of Androgenic Alopecia in Males
The purpose of this study is to evaluate the change in terminal hair count at 16 and 26 weeks compared to baseline measurements.
- Conditions
- Androgenetic Alopecia, Hair Loss, Male Pattern Baldness
- Trial name
- NCT00947219
- Testing
- HairMax LaserComb, Control device
- Where
- 3 sites in United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Lexington International, LLC
Androgenic Alopecia
Computer-Assisted Hair Implantation Using ARTAS System VS Manual Implantation Technique Hair Restoration Study
To investigate and compare the safety and effectiveness of the ARTAS™ System to manual hair follicle implantation method following a nine month period of post-procedure evaluation.
- Trial name
- NCT02914587
- Testing
- ARTAS System, Manual Implantation
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Restoration Robotics, Inc.
Androgenetic Alopecia
A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
Open label study to assess safety, tolerability, and efficacy of ATI-50002 in male and female subjects with androgenetic alopecia.
- Trial name
- NCT03495817
- Testing
- ATI-50002
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Aclaris Therapeutics, Inc.
Androgenic Alopecia
Assessment of the Effects and Tolerance of the RV4986A Lotion in Men With AGA After Hair Transplant
Alopecia involves a diminution of visible hair that can have significant psychosocial effects and impairment of quality of life.
- Trial name
- NCT06576492
- Testing
- RV4986A lotion
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Androgenetic Alopecia
Minoxidil Response Testing in Males With Androgenetic Alopecia
Topical minoxidil is the most common drug used for the treatment of AGA in men. While topical minoxidil exhibits a good safety profile, the efficacy in the overall population remains relatively low i.e., 30-40% re-grow hair.
- Trial name
- NCT02198261
- Testing
- 5% minoxidil topical foam
- Where
- 5 sites in United States, Australia and 2 more
- Volunteers
- 300 people
- Sponsor
- Applied Biology, Inc.
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002013)
The purpose of the study is to evaluate the ability of injections Ji Gami(TM) to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451073
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 6 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Androgenetic Alopecia
Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration
The study is a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Healthy Male Subjects with Androgenetic Alopecia to Evaluate the Safety, Tolerability and Pharmacokinetics of KX-826 Following…
- Trial name
- NCT04984707
- Testing
- KX0826
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Androgenetic Alopecia
Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men
The goal of this study is to measure the safety, tolerability, and the hair growth response to topical DLQ01 solutions in comparison to the vehicle and a comparator solution in 120 males with Androgenetic Alopecia.
- Trial name
- NCT05636904
- Testing
- prostaglandin F2a analogue in vehicle solution high dose, prostaglandin F2a analogue in vehicle solution low dose, active ingredient-free vehicle solution to DLQ01
- Where
- 2 sites in Australia
- Volunteers
- 120 people
- Sponsor
- Dermaliq Therapeutics, Inc.
Androgenetic Alopecia
To Evaluate the Pharmacokinetics and Safety of AD-208
To evaluate pharmacokinetics and safety of AD-208.
- Trial name
- NCT04214808
- Testing
- AD-208, Avodart Soft Capsule 0.5mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Androgenetic Alopecia
A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss
The primary purpose of the study is to evaluate the efficacy of a topical 5% minoxidil formulation in males for the treatment of pattern hair loss.
- Trial name
- NCT00151515
- Testing
- minoxidil
- Where
- 15 sites in United States
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Androgenetic Alopecia
Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA
The study is a two part study, designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK.
- Trial name
- NCT06393452
- Testing
- PP405 0.05% Topical Gel, Topical Vehicle Gel
- Where
- 8 sites in United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Pelage Pharmaceuticals, Inc.
Androgenetic Alopecia
Photosensitization Study in Androgenetic Alopecia
This study evaluates the potential for induction of photosensitization by P-3074 0.25% finasteride cutaneous solution compared to that of placebo vehicle cutaneous solution and a negative control (0.9% sodium chloride, NaCl)
- Trial name
- NCT02791243
- Testing
- Finasteride 0.25%, Negative Control
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Polichem S.A.
Androgenetic Alopecia
Treatment of Androgenetic Alopecia in Males and Females
The purpose of this study is to evaluate the efficacy of Low Level Laser and Light Therapy system configured in a novel product called the TopHat 655 system, for promoting hair growth in males and females diagnosed with…
- Trial name
- LLLT (NCT01437163)
- Testing
- TopHat 655 rejuvenation system, Laser and/or Light Hair Rejuvenation System
- Where
- 4 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Apira Science, Inc.
Androgenetic Alopecia
Clinical Trial in Females for Female Pattern Hair Loss
This is a six month clinical trial to evaluate the effectiveness and safety in women with Female Pattern Hair Loss (FPHL), comparing a 5% minoxidil topical foam (MTF) formulation applied once a day versus a topical foam vehicle…
- Trial name
- NCT01226459
- Testing
- 5% Minoxidil Topical Foam, Vehicle Topical Foam
- Where
- 17 sites in United States, France and 2 more
- Volunteers
- 404 people
- Sponsor
- Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
Alopecia, Alopecia, Androgenetic
Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia
This study will investigate the safety, tolerability, and pharmacokinetics of new formulation of bimatoprost following topical application in patients with alopecia.
- Conditions
- Alopecia, Alopecia, Androgenetic, Baldness
- Trial name
- NCT01189279
- Testing
- bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Allergan
Androgenetic Alopecia, Hair Loss
Treatment of Androgenetic Alopecia in Males
The purpose of this study is to evaluate the efficacy of the HairMax LaserComb 2009 7 Beam model in promoting hair growth in males diagnosed with androgenetic alopecia when treatment is applied as directed.
- Conditions
- Androgenetic Alopecia, Hair Loss, Male Pattern Baldness
- Trial name
- NCT00947505
- Testing
- HairMax LaserComb 2009, 7 Beam, HairMax LaserComb
- Where
- 2 sites in United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Lexington International, LLC
Androgenetic Alopecia
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
The purpose of this study is to characterize the safety, tolerability, and efficacy of topical SM04554 solution (0.15% and 0.25%) applied to the scalp of male subjects with Androgenetic Alopecia (AGA).
- Trial name
- NCT02275351
- Testing
- Topical SM04554 solution, Topical vehicle solution
- Where
- 24 sites in United States
- Volunteers
- 302 people
- Sponsor
- Biosplice Therapeutics, Inc.
AGA
A Phase 3 Clinical Study Patients With Androgenetic Alopecia (AGA)
A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Clinical Study ,the mean change from baseline in vertex target area hair count (TAHC) after treatment for 24 weeks.
- Trial name
- NCT05135468
- Testing
- CU-40102 Spray
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Cutia Therapeutics（Wuxi）Co.,Ltd
Androgenic Alopecia
A Clinical Study to Evaluate the Efficacy and Safety of Ultra in Promoting Hair Regrowth
The goal of this clinical study is to evaluate the efficacy and safety of the Ultra device for the treatment of hair regrowth by assessing the improvement of hair density and hair shaft diameter.
- Trial name
- NCT07588243
- Testing
- Low Level Laser Therapy
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- CynosureLutronic
Androgenetic Alopecia
Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
The purpose of this six month study is to show that dutasteride is safe and more effective than placebo, and at least as safe and effective as finasteride in treating hair loss in men with androgenetic alopecia.
- Trial name
- NCT01231607
- Testing
- 1mg Finasteride active, 0.02mg dutasteride, 0.1mg dutasteride
- Where
- 39 sites in Argentina, Chile and 7 more
- Volunteers
- 917 people
- Sponsor
- GlaxoSmithKline